Loading company…
Nanoligent develops nanotechnology-based medicines and targeted therapies for metastatic cancers.
Founded in 2017 in Spain, Nanoligent uses engineering and nanobiotechnology to develop targeted drug therapies for more than 20 metastatic cancer types. Its portfolio includes NNL-121, a protein nanoparticle targeting CXCR4 for metastatic colorectal cancer. In October 2025, it raised EUR 12 million in venture funding led by Inveready Asset Management, with participation from Center for Technological & Industrial Development, Clave Capital, i&i Bio, Italian Angels for Growth, and AVANTECA Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in